flowchart LR
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is effective against| herpes_zoster["herpes zoster"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is effective against| postherpetic_neuralgia["postherpetic neuralgia"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is effective against| ophthalmicus["ophthalmicus"]
    CDC["CDC"] -->|recommends| two_dose_series["two-dose series"]
    two_dose_series["two-dose series"] -->|consists of| injections["injections"]
    injections["injections"] -->|are given| 2_6_months_apart["2-6 months apart"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|has effectiveness| vaccine_effectiveness_VE["vaccine effectiveness (VE)"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|is 56.1% for| one_dose["one dose"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|is 67.9% for| two_doses["two doses"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is recommended for| 65_years_or_older["65 years or older"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is recommended for| 50_years_or_older["50 years or older"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is effective in| immunocompromised["immunocompromised"]
    recombinant_zoster_vaccine_RZV["recombinant zoster vaccine (RZV)"] -->|is effective in| immunocompetent["immunocompetent"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|is epidemiologist at| University_of_North_Carolina_School_of_Medicine["University of North Carolina School of Medicine"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|said| superior_effectiveness_of_two_doses_compared_to_one["superior effectiveness of two doses compared to one"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|said| information_helpful_for_patients_hesitant_about_second_dose["information helpful for patients hesitant about second dose"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|said| low_representation_of_Black_and_Hispanic_individuals_led_to_imprecise_estimates["low representation of Black and Hispanic individuals led to imprecise estimates"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|said| vaccine_recommendations_should_not_consider_race_or_ethnicity["vaccine recommendations should not consider race or ethnicity"]
    Shirin_Mazumder["Shirin Mazumder"] -->|is infectious diseases specialist at| University_of_Tennessee_Health_Science_Center["University of Tennessee Health Science Center"]
    Shirin_Mazumder["Shirin Mazumder"] -->|said| study_important_for_assessing_vaccine_performance_in_older_adults["study important for assessing vaccine performance in older adults"]
    Shirin_Mazumder["Shirin Mazumder"] -->|said| barriers_include_access,_lack_of_insurance,_side_effects["barriers include access, lack of insurance, side effects"]
    Shirin_Mazumder["Shirin Mazumder"] -->|said| solutions_include_reminder_systems,_vaccine_programs,_open_conversations["solutions include reminder systems, vaccine programs, open conversations"]
    study["study"] -->|was published in| Annals_of_Internal_Medicine["Annals of Internal Medicine"]
    study["study"] -->|used data from| Medicare["Medicare"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was lower in| 85_years_or_older["85 years or older"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was lower in| Black_individuals["Black individuals"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was similar in| immunocompromised_and_immunocompetent["immunocompromised and immunocompetent"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was 44% in| 85_years_or_older["85 years or older"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was 20% in| Black_individuals["Black individuals"]
    vaccine_effectiveness_VE["vaccine effectiveness (VE)"] -->|was 55% in| non_Black_individuals["non-Black individuals"]
    Nadja_A._Vielot["Nadja A. Vielot"] -->|and colleagues are analyzing| private_insurance_claims["private insurance claims"]
    private_insurance_claims["private insurance claims"] -->|are used to assess| safety_of_shingles_vaccine["safety of shingles vaccine"]
    barriers_to_vaccination["barriers to vaccination"] -->|include| access["access"]
    barriers_to_vaccination["barriers to vaccination"] -->|include| lack_of_insurance["lack of insurance"]
    barriers_to_vaccination["barriers to vaccination"] -->|include| hesitancy["hesitancy"]
    solutions_to_barriers["solutions to barriers"] -->|include| reminder_systems["reminder systems"]
    solutions_to_barriers["solutions to barriers"] -->|include| vaccine_programs["vaccine programs"]